GlassScriptPhysician profile
Michael Andrew Steingart
NPI 1316065337
$692.84
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $318 · 2020: $82.22 · 2021: $144 · 2022: $135 · 2023: $14.04.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $196.29 | 2019-2023 | Grafix Pl |
| Osiris Therapeutics INC. | $144.78 | 2019 | |
| Fidia Pharma USA INC. | $112.99 | 2019-2022 | |
| Orthogenrx INC. | $29.61 | 2019 | |
| Electronic Waveform Lab, INC. | $27.41 | 2021 | |
| Theragen, INC. | $26.45 | 2022 | |
| Si-Bone, INC. | $23.78 | 2019 | |
| Bioventus LLC | $17.88 | 2021 | |
| Biotissue Holdings INC. | $17.15 | 2022 | |
| Orthofix Medical, INC. | $16.91 | 2019 | |
| Zimmer Biomet Holdings, INC. | $16.53 | 2019 | |
| Vericel Corporation | $14.59 | 2021 | |
| Team_makena_llc | $12.97 | 2019 | |
| Assertio Therapeutics, INC. | $12.21 | 2020 | |
| Hikma Pharmaceuticals USA | $11.91 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $11.38 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Steingart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.